Get the Stockscreener App
7.57
2.07%
-0.16
After Hours:
7.50
-0.07
-0.92%
Bioage Labs Inc stock is traded at $7.57, with a volume of 278.09K.
It is down -2.07% in the last 24 hours and up +28.74% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$7.73
Open:
$7.8
24h Volume:
278.09K
Relative Volume:
1.00
Market Cap:
$271.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.39%
1M Performance:
+28.74%
6M Performance:
+80.24%
1Y Performance:
-67.92%
1-Day Range:
$7.52
$7.87
1-Week Range:
$7.245
$8.15
52-Week Range:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
7.57 | 277.12M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Obesity Drugmaker Escapes Clinical Trial Securities Suit - Law360
BioAge Labs (NASDAQ:BIOA) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
BioAge Beats IPO Investor Lawsuit Over Weight Loss Trial End - Bloomberg Law News
Why BioAge Labs Inc. (Y7G) stock stays undervaluedMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Does BioAge Labs Inc. show high probability of reboundJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Sector ETF performance correlation with BioAge Labs Inc.Earnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
How BioAge Labs Inc. stock compares to growth peers2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Automated trading signals detected on BioAge Labs Inc.July 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Analyzing drawdowns of BioAge Labs Inc. with statistical toolsJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Can BioAge Labs Inc. stock resist sector downturnsQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Order flow analysis tools used on BioAge Labs Inc.CEO Change & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-30 23:35:20 - newser.com
Using data models to predict BioAge Labs Inc. stock movementBuy Signal & Weekly Stock Performance Updates - newser.com
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
Why BioAge Labs Inc. stock could be next big winnerBull Run & Verified Stock Trade Ideas - newser.com
What candlestick patterns are forming on BioAge Labs Inc.Market Weekly Review & AI Driven Price Predictions - newser.com
Is BioAge Labs Inc. stock attractive for long term wealth building2025 Trading Volume Trends & Growth-Oriented Investment Plans - newser.com
Citigroup Maintains BioAge Labs (BIOA) Buy Recommendation - Nasdaq
Bioage Labs (BIOA) Receives Raised Price Target from Citigroup | - GuruFocus
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? - AOL.com
Is BioAge Labs Inc. (Y7G) stock supported by free cash flow2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Analyzing BioAge Labs Inc. with risk reward ratio chartsWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
BioAge Labs (BIOA) Price Target Increased by 71.43% to 8.16 - Nasdaq
Positive Week for BioAge Labs, Inc. (NASDAQ:BIOA) Institutional Investors Who Lost 68% Over the Past Year - 富途牛牛
How strong is BioAge Labs Inc. (Y7G) stock earnings growthJuly 2025 Technicals & Technical Pattern Alert System - newser.com
Will BioAge Labs Inc. stock benefit from infrastructure spendingJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Fundação Cultural do Pará
Published on: 2025-10-27 22:26:35 - newser.com
How to Value Scintilla Commercial Credit Limited Stock Using DCF AnalysisRSI Overbought/Oversold & Low Entry Investment Ideas - earlytimes.in
Is BioAge Labs Inc a good long term investmentSwing Trading Watchlist & Free Grow Wealth With Picks - earlytimes.in
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):